| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372732A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 01/02/2004 | EP1372728A1 Compositions comprising an o/w emulsion containing conjugated linoleic acid |
| 01/02/2004 | EP1372726A1 Methods for reducing fat by administration of adiponectin |
| 01/02/2004 | EP1372719A2 Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer |
| 01/02/2004 | EP1372716A2 Blood cell production via activation of the hemoglobin scavenger receptor (cd163) |
| 01/02/2004 | EP1372710A2 Mva expressing modified hiv envelope, gag, and pol genes |
| 01/02/2004 | EP1372709A2 Intimins for the prevention or treatment of infections: i |
| 01/02/2004 | EP1372703A2 Matrix stabilized enzyme crystals and methods of use |
| 01/02/2004 | EP1372702A1 Method of treatment of hypoxia/ischaemia related blood flow resistance |
| 01/02/2004 | EP1372701A2 Methods of therapy for hiv infection |
| 01/02/2004 | EP1372700A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 01/02/2004 | EP1372699A1 Method of improving the growth performance of an animal |
| 01/02/2004 | EP1372698A2 Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders |
| 01/02/2004 | EP1372697A2 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c, and corresponding screening method |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372694A1 Liposome targeting of matrix metalloproteinase inhibitors |
| 01/02/2004 | EP1372693A2 Peptides for the treatment of wound contracture |
| 01/02/2004 | EP1372692A2 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 01/02/2004 | EP1372691A2 Mucin peptide with immunoenhancing properties |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372689A2 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 01/02/2004 | EP1372688A2 Somatostatin antagonists |
| 01/02/2004 | EP1372687A1 METHODS FOR REGULATING BUD-HYPHA TRANSITIONS AND cAMP LEVELS BY THE ADENYLATE CYCLASE-ASSOCIATED PROTEIN GENE, i CAP1 /i |
| 01/02/2004 | EP1372678A2 Vectors, compositions and methods for treating a vascular disorder |
| 01/02/2004 | EP1372652A2 Combination of a taxane and a cyclin-dependent kinase |
| 01/02/2004 | EP1372650A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 01/02/2004 | EP1372641A1 Enteral formulation |
| 01/02/2004 | EP1372634A2 Fumaric acid amides |
| 01/02/2004 | EP1372631A1 Method and formula for anti-tumor and anti-matastatic effect |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372621A1 Novel use of tyrosine kinase inhibitor |
| 01/02/2004 | EP1372620A2 Methods for restoring cognitive function following systemic stress |
| 01/02/2004 | EP1372618A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer |
| 01/02/2004 | EP1372615A1 Compounds and compositions for delivering active agents |
| 01/02/2004 | EP1372606A2 In-situ gel formation of pectins |
| 01/02/2004 | EP1372412A2 Composition improving age-related physiological deficits and increasing longevity |
| 01/02/2004 | EP1250146B1 Use of botulinum toxins for treating diabetes |
| 01/02/2004 | EP1235830B1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| 01/02/2004 | EP0871664B1 Mobilization of hematopoietic stem cells using a chemokine |
| 01/02/2004 | EP0746343B1 Bioartificial kidney devices coated with cells suitable for use in vivo or ex vivo |
| 01/02/2004 | EP0719343B1 Adeno-associated viral (aav) liposomes and methods related thereto |
| 01/01/2004 | US20040003425 Nav2 channel gene-deficient non-human animals |
| 01/01/2004 | US20040003422 An expression cassette containing the proopiomelanocortin (POMC) enhancer, and a nucleic acid sequence encoding POMC contains at least one exon, wherein a polylinker having an unique site for restriction enzyme is inserted into the exon; gene regulates weight and fat mass |
| 01/01/2004 | US20040003421 Lysosomal proteins produced in the milk of transgenic animals |
| 01/01/2004 | US20040003418 Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer |
| 01/01/2004 | US20040003079 Systems and methods to regulate use of consumer devices and services |
| 01/01/2004 | US20040002591 50 human secreted proteins |
| 01/01/2004 | US20040002590 Tumour necrosis factor peptide binding antibodies |
| 01/01/2004 | US20040002589 Tumour necrosis factor peptide binding antibodies |
| 01/01/2004 | US20040002588 Ligands which bind to human tumour necrosis factor alpha (TNF) in a manner that modifies the TNF |
| 01/01/2004 | US20040002584 Proteins, polynucleotides encoding them and methods of using the same |
| 01/01/2004 | US20040002582 Miniprotein ligands and other polypeptides and methods for making and using same |
| 01/01/2004 | US20040002581 Peptides and use thereof in therapeutic agents against HIV infection |
| 01/01/2004 | US20040002558 Osteogenic paste compositions and uses thereof |
| 01/01/2004 | US20040002537 Multiple sclerosis; central nervous system disorders; side effect reduction |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002487 Bone disorders; osteoporosis; oral diseases; antiarthritic agents |
| 01/01/2004 | US20040002479 Proteasome inhibitors; bone disorders |
| 01/01/2004 | US20040002474 IFN-alpha homologues |
| 01/01/2004 | US20040002473 Pain modulation; incotinence therapy; central nervous system disorders |
| 01/01/2004 | US20040002471 Human nucleic acid sequences which are overexpressed in normal pancreas tissue |
| 01/01/2004 | US20040002470 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease |
| 01/01/2004 | US20040002469 Administering genetic engineered polynucleotide which codes heat shock protein; induce immunology response |
| 01/01/2004 | US20040002468 Methods of treating diabetes and other blood sugar disorders |
| 01/01/2004 | US20040002467 Antisense modulation of ADAM12 expression |
| 01/01/2004 | US20040002466 Releasing interferon from complex of interferon and nucleic acids; antitumor agents, viricide, induction immunology response |
| 01/01/2004 | US20040002461 Amelioration of the development of cataracts and other ophthalmic diseases |
| 01/01/2004 | US20040002460 Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom |
| 01/01/2004 | US20040002459 Nucleic acids encoding kringle 1-5 region fragments of plasminogen |
| 01/01/2004 | US20040002458 Pharmaceutical compositions and methods using natriuretic peptides |
| 01/01/2004 | US20040002457 Prevention binding of cells to protein; therapy for Aids; viricides |
| 01/01/2004 | US20040002454 Administering polypeptides; cardiovascular disorders |
| 01/01/2004 | US20040002453 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/01/2004 | US20040002452 Neutrophil cytoplasmic antibodies; bactericides, antiulcer agents, antiinflammatory agents, inflammatory bowel disease, autoimmune diseases |
| 01/01/2004 | US20040002451 Antiinflammatory agents; stability, reduced viscosity; immobilization |
| 01/01/2004 | US20040002450 Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 01/01/2004 | US20040002449 METH1 and METH2 polynucleotides and polypeptides |
| 01/01/2004 | US20040002448 Viricides; induction immunology response |
| 01/01/2004 | US20040002447 Induction of insulin expression |
| 01/01/2004 | US20040002446 Central nervous system disorders; brain disorders; administering genetic engineered thrombomodulin |
| 01/01/2004 | US20040002445 Using gonadotrophin releasing hormone inhibitor; forming testosterone; therapy for sexual disorders |
| 01/01/2004 | US20040002444 Promote tissue regeneration |
| 01/01/2004 | US20040002442 Antidiabetic agents; obesity therapy; autoimmune disease |
| 01/01/2004 | US20040002153 Modulation of PTEN expression via oligomeric compounds |
| 01/01/2004 | US20040002152 Oligonucleotides specifically hybridizable with nucleic acids encoding P2X4; P2X4 is a subfamily of the purinoreceptors that are ligand-gated ion channels that respond to the endogenous occurring neurotransmitter Adenosine Triphosphate |
| 01/01/2004 | US20040002151 Antisense modulation of selenophosphate synthetase 2 expression |
| 01/01/2004 | US20040002150 Antisense modulation of hypothetical protein LOC51249 expression |
| 01/01/2004 | US20040002140 Growth factor homolog ZVEGF4 |
| 01/01/2004 | US20040002139 Methods for making recombinant proteins using apoptosis inhibitors |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002120 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/01/2004 | US20040002117 Immunosuppressive agents of given formula; prevents dephosphorylation |
| 01/01/2004 | US20040002114 Nucleic acids encoding a G-protein coupled receptor involved in islet cell signaling |
| 01/01/2004 | US20040002113 Detection and treatment methods for type I diabetes |
| 01/01/2004 | US20040002112 Identifying and/or quantitating proteins differentially expressed in one or more specific stage(s) of adipocyte differentiation, using mass spectrometry |
| 01/01/2004 | US20040002103 Synthetic ligation reassembly in directed evolution |
| 01/01/2004 | US20040002099 Genes and genetic elements associated with sensitivity to platinum-based drugs |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |